CDK4 and breast carcinoma: The specificity of the CDK4/6Is, and evidence for increased CDK activity in HR+ breast cancers suggested the potential utility of CDK4/6Is in combination with endocrine therapy for therapy-specific breast cancer subtypes [24,25] (Figure 1).